- Home
- MEC vs CTNM Comparison
MEC vs CTNM Comparison
Compare MEC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEC | CTNM |
|---|---|---|
| Founded | 1945 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.2M | 328.1M |
| IPO Year | 2019 | 2024 |
Fundamental Metrics
Financial Performance| Metric | MEC | CTNM |
|---|---|---|
| Price | $18.39 | $11.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $22.00 | $20.00 |
| AVG Volume (30 Days) | 216.0K | ★ 254.5K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $533,523,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.73 | N/A |
| P/E Ratio | $31.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.72 | $3.35 |
| 52 Week High | $19.25 | $15.25 |
Technical Indicators
Market Signals| Indicator | MEC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 64.40 | 51.22 |
| Support Level | $16.81 | $11.50 |
| Resistance Level | $19.25 | $13.48 |
| Average True Range (ATR) | 0.79 | 0.70 |
| MACD | 0.20 | 0.08 |
| Stochastic Oscillator | 77.07 | 41.98 |
Price Performance
Historical ComparisonAbout MEC Mayville Engineering Company Inc.
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, power sports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly and logistic services.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.